Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promote: Tenofovir Amibufenamide in Chronic Hepatitis B with Normal ALT
NCT05797714Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir + amibufenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Percentage of Participants with Hepatitis B Virus (HBV) DNA < 20 IU/mL at 48 weeks. Started Jun 2022; status: active, not recruiting.
02
Drugs
tenofovir + amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05797714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797714.